Escherichia coli–expressed near full length HIV-1 envelope glycoprotein is a highly sensitive and specific diagnostic antigen by Talha, Sheikh M. et al.
RESEARCH ARTICLE Open Access
Escherichia coli–expressed near full length HIV-1
envelope glycoprotein is a highly sensitive and
specific diagnostic antigen
Sheikh M Talha1,2*, Satish Kumar Nemani2, Teppo Salminen1, Sushil Kumar2, Sathyamangalam Swaminathan2,
Tero Soukka1, Kim Pettersson1 and Navin Khanna2
Abstract
Background: The Human Immunodeficiency Virus type 1 (HIV-1) envelope glycoprotein gp160, useful in detecting
anti-HIV-1 antibodies, is difficult to express in heterologous hosts. The major hurdles are its signal sequence, strong
hydrophobic regions and heavy glycosylation. While it has not been possible to express full length recombinant
(r)-gp160 in E. coli, it can be expressed in insect and mammalian cells, but at relatively higher cost. In this work, we
report E. coli-based over-expression of r-gp160 variant and evaluate its performance in diagnostic immunoassays for
the detection of anti-HIV-1 antibodies.
Methods: A deletion variant of r-gp160 lacking hydrophobic regions of the parent full length molecule was
expressed in E. coli and purified to near homogeneity using single-step Ni(II)-affinity chromatography. Biotinylated
and europium(III) chelate-labeled versions of this antigen were used to set up one- and two-step time-resolved
fluorometric double antigen sandwich assays. The performance of these assays was evaluated against a collection
of well-characterized human sera (n=131), that included an in-house panel and four commercially procured panels.
Results: In-frame deletion of three hydrophobic regions, spanning amino acid residues 1–43, 519–538 and
676–706, of full length HIV-1 gp160 resulted in its expression in E. coli. Both the one- and two-step assays
manifested high sensitivity unambiguously identifying 75/77 and 77/77 HIV-1 positive sera, respectively. Both assays
also identified all 52 HIV-seronegative sera correctly. Between the two assays, the mean signal-to-cutoff value of the
two-step assay was an order of magnitude greater than that of the one-step assay. Both assays were highly specific
manifesting no cross-reactivity towards antibodies specific to other viruses like hepatitis B, C, and human T cell
leukemia viruses.
Conclusions: This study has demonstrated the expression of r-gp160 variant in E. coli, by deletion of hydrophobic
regions, and its purification in reasonable yields. This underscores the potential for cost saving in antigen
production. Evaluation of this antigen in a double antigen sandwich two-step assay showed it to be a highly
sensitive and specific HIV-1 diagnostic reagent. The amenability of this assay to the one-step format suggests its
potential utility in developing a rapid point-of-care HIV-1 diagnostic test.
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Background
Human immunodeficiency virus (HIV), a member of the
family Retroviridae, is the causative agent of acquired
immunodeficiency syndrome (AIDS), characterized by
profound immune system dysfunction [1]. Recent esti-
mates of the global AIDS burden indicate that there
were 2.7 million new infections (bringing the total num-
ber to ~34 million infected individuals worldwide) and
1.8 million deaths in 2010 [2]. Diagnostic tests play a
critical role in curtailing the spread of HIV, through
early detection of infection to identify individuals need-
ing antiviral therapy, and in screening blood and blood
related products [3-5]. Most commonly used HIV
screening tests are based on the principle of enzyme im-
munoassay (EIA) that detect either the antibodies (first,
second and third generation EIAs) or p24 antigen as well
(fourth generation EIA) [6,7]. The envelope glycoprotein
(gp160) of HIV-1 is well documented as a viral antigen
that presents immunodominant regions for serodiagno-
sis of HIV-1 infections [8-11]. Native gp160 which can
be obtained by HIV-1 infection of H9 cells in tissue cul-
ture [12] has been shown to detect earliest HIV-1 sero-
conversion in different EIAs [12,13]. The inherent
biohazard entailed in gp160 production can be circum-
vented through recombinant expression. However, the
gp160 antigen, with its strong hydrophobic regions and
heavy glycosylation, is a difficult candidate for heterol-
ogous expression and purification [8,14,15]. Neverthe-
less, recombinant (r)-gp160 can be expressed in insect
and mammalian cells, and purified by immunoaffinity
or lectin affinity chromatography [14-18]. Though both
native and r-gp160 are commercially available, the ex-
pensive expression and purification systems increase
the production cost of the protein, and in turn contrib-
ute to increased cost of HIV testing.
One way to cut down the cost of HIV testing would be
to try and exploit the high production potential of pro-
karyotic expression hosts to produce r-gp160. However,
full-length r-gp160 expression in E. coli has not been suc-
cessful. It was reported that a plasmid containing full-
length HIV-1 gp160 insert was toxic to E. coli resulting in
either elimination or rearrangement of the insert [19]. It
has been reported that there are two hydrophobic regions
in the C-terminal half of gp160 [8]. In this study, we
deleted these two regions, as well as the hydrophobic sig-
nal peptide, implicated in low expression in mammalian
cells [14,15], to create a deletion mutant, Δgp160, and
found this to be expressed quite well in E. coli, leading to
the purification of 15–20 mg r-Δgp160 antigen per liter
of induced culture. Compared to the native full-length
gp160, the r-Δgp160 antigen developed in this study is
almost full-length, lacking just ~10% of the parent
sequences (representing three hydrophobic regions). We
used two versions of this antigen to set up one- and
two-step time-resolved fluorometric (TRF) double anti-
gen sandwich (bridge) assays as described earlier [20].
One version of the antigen was biotinylated [immobilized
on streptavidin (SA)-coated microtiter wells, to capture
anti-HIV antibodies] and the other, labeled with a euro-
pium (Eu3+) chelate (as a tracer to reveal bound anti-
bodies). By testing a collection of well-characterized
human sera (n=131) in these assays, we provide evidence
to show that the E.coli-expressed r-Δgp160 antigen is a
potential diagnostic tool of high sensitivity and specificity
for the detection of anti-HIV-1 antibodies.
Methods
Materials
E. coli host strains DH5α and BL21(DE3), used for clon-
ing and expression, respectively, were purchased from
Invitrogen Life Technologies (Carlsbad, CA, USA). Plas-
mid pET-28a(+) was from Novagen (Madison, WI, USA).
Plasmids pTrxBAP and pBirA have been described before
[20,21]. Enzymes for routine cloning work were procured
from MBI Fermentas (Burlington, Canada). Ni-NTA
super flow resin and isopropyl-β-D-thiogalactopyranoside
(IPTG) were from Qiagen (Hilden, Germany), and Cal-
biochem-EMD Biosciences (La Jolla, CA, USA), respect-
ively. The intrinsically fluorescent isothiocyanate activated
nonadentate Eu3+-chelate [22,23] and biotin isothiocyan-
ate [24] for antigen labeling were synthesized as before.
Nucleic Acid Purification (NAP) Sephadex G-25 col-
umns were procured from GE Healthcare (Uppsala, Swe-
den). SA-coated normal capacity low-fluorescent microtiter
plates were obtained from Kaivogen Oy (Turku, Finland).
A collection of 131 human sera samples was
assembled for the study. This consisted of one in-house
panel and 4 commercially procured panels. The in-
house panel of 59 sera samples (consisting of 22 HIV
positive and 37 HIV negative sera), pre-screened using
Vidas HIV Duo Quick kit (bioMérieux SA, Marcy
I’Etoile, France), was obtained from the Department of
Virology, University of Turku. These sera samples were
collected as per the guidelines of Ethics Committee of
the Turku University Hospital. Well-characterized
worldwide HIV performance panel (WWRB 302–01 to
WWRB 302–30), HIV-1 seroconversion panel (PRB
931–01 to PRB 931–09), anti-HIV-1 low titer perform-
ance panel (PRB 108–1 to PRB 108–15) and viral co-
infection panel (PCA 201–01 to PCA 201–25) were pur-
chased from SeraCare Life Sciences (Milford, MA,
USA). In total, there were 77 anti-HIV-1 positive, 2 anti-
HIV-2 positive and 52 anti-HIV negative samples.
Generation of recombinant gp160 antigens
The 760 amino acid (aa) residue long r-Δgp160 antigen
was designed by eliminating the signal sequence (aa 1–
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43) and two internal hydrophobic regions (aa 519–538
and 676–706) of HIV-1 (strain NL4-3). The correspond-
ing synthetic gene, codon-optimized for E. coli expres-
sion was obtained from Geneart (Regensburg, Germany),
and used to express two variants of the encoded recom-
binant antigen. This synthetic gene was inserted into (i)
pET-28a(+), in-frame with the vector-encoded 6x-His tag
and stop codon at its carboxyl end, to express r-Δgp160
antigen, and (ii) pTrxBAP in frame with the vector-
encoded Trx (thioredoxin)-6x-His tag-BAP sequences at
the amino terminus, to express the r-Trx-BAP-Δgp160
antigen. The resultant plasmids were introduced separ-
ately into E. coli BL21(DE3), and induced to express with
1 mM IPTG. In order to achieve biotinylation of the
r-Trx-BAP-Δgp160 antigen in vivo, E. coli cells expressing
this antigen were co-transformed with IPTG-inducible
biotin ligase expressing plasmid pBirA and cultured in
medium supplemented with biotin (10 μg/ml).
As both recombinant protein variants were associated
with the insoluble fraction, they were purified from
induced cells under denaturing conditions [20]. Briefly,
induced cell pellets were re-suspended in lysis buffer
(6 M guanidine HCl/20 mM Tris–HCl/300 mM NaCl/10%
glycerol/0.1% sodium deoxycholate/1% Tween-20/10 mM
β-mercaptoethanol/20 mM imidazole, pH 8) and lysed by
sonication at 4°C (Sonics Vibracell sonicator). The result-
ing lysate was clarified and chromatographed on a 5 ml
Ni-NTA super flow resin column. After washing the
column (wash buffer was similar to lysis buffer lacking
sodium deoxycholate with the exception that 6 M
Guanidine-HCl was replaced by 8 M urea), elution was
performed using a linear imidazole gradient (20–500
mM) in wash buffer. All the eluted fractions were ana-
lyzed by SDS–PAGE, the peak fractions were pooled to-
gether, filtered through 0.22 μm membrane and stored in
1 ml aliquots at a concentration of about 1 mg/ml at
−20°C until further use. One aliquot was thawed at a
time, heat-treated at 80°C for 90 seconds, snap-cooled in
ice bath and the buffer was changed to 50 mM sodium
carbonate buffer, pH 9.8 using NAP-5 or NAP-10
column, for subsequent labeling reaction.
Preparation of labeled antigens
The r-Δgp160 antigen was labeled with a 30-fold molar
excess of Eu3+-chelate at 4°C for 16–20 hours in 50 mM
sodium carbonate buffer, pH 9.8, essentially as described
before [20]. The r-Trx-BAP-Δgp160 (which failed to be
efficiently biotinylated in vivo) was in vitro (chemically)
biotinylated with a 40-fold molar excess of biotin iso-
thiocyanate. The reaction was performed in 50 mM so-
dium carbonate buffer, pH 9.8, at room temperature
(RT) for 4 hours. Both the unincorporated labels were
removed by passing the reaction mixtures sequentially
through NAP-5 and NAP-10 columns. For the sake of
simplicity, Eu3+-chelate labeled r-Δgp160 and chemically
biotinylated r-Trx-BAP-Δgp160 antigens are referred to
as r-Δgp160-Eu3+ and r-Δgp160-Bio, respectively. The
labeled antigens were supplemented with 0.1% bovine
serum albumin and 0.05% sodium azide, filtered through
0.22 μm membranes and stored at 4°C, until further use.
In-house TRF double antigen sandwich assays
Either r-Δgp160-Bio antigen (600 ng/100 μl assay buffer/
well) or the previously reported [20] in vivo biotinylated
r-Bio-HIV-1env antigen (200 ng/100 μl assay buffer/well)
was immobilized on SA-coated microtiter wells. The assay
buffer was 50 mM sodium carbonate, pH 9.6 (containing
25 mM NaCl/0.1% Tween-20/2.5% BSA/1.25% sucrose/
0.06% γ-globulins from bovine blood/0.05% NaN3). Bind-
ing of biotinylated antigen to SA-coated microtiter wells
was allowed to proceed for 1 hour at RT with shaking.
The wells were then rinsed twice with wash buffer (154
mM NaCl/0.5 M KCl/0.1% Tween-20/50 mM potassium
phosphate buffer, pH 7.2). These antigen-coated wells
were used in one- and two-step assay formats as
described below.
In the one-step assay (performed only with r-Δgp160-
Bio antigen-coated well), a mixture of 50 μl serum,
diluted (1:10) in assay buffer, plus 50 μl assay buffer con-
taining 100 ng r-Δgp160-Eu3+, was added to each well
and incubated for 1 hour at RT with shaking. The wells
were washed 7 times with wash buffer. Time-resolved
fluorescence for Eu3+-chelate was measured (λex:340nm;
λem:615nm) from dry wells using Victor
3V 1420 Multila-
bel counter (modified standard europium protocol; meas-
urement height 5 mm).
In the two-step assay, 100 μl serum (diluted 1:20 in
assay buffer) was added into each well and incubated for
1 hour at RT with shaking. Following 4 washes, 100 μl
assay buffer containing either 100 ng r-Δgp160-Eu3+
(where r-Δgp160-Bio was immobilized as capture antigen)
or r-HIV-1env-Eu3+ (where r-Bio-HIV-1env was immobi-
lized as capture antigen) was added to each well and
incubated for 1 hour at RT with shaking. The wells were
washed 7 times with wash buffer and read as above.
Data analysis
Each assay was evaluated with all the sera on the same
day and the results obtained from different assays in sin-
gle analysis were compared. Sera were designated as ei-
ther positive or negative using cutoff values of 1000
counts per second (cps) and 924 cps, respectively for the
one- and two-step r-Δgp160-based assays developed in
this study. A cutoff value of 818 cps was used for the
two-step r-HIV-1env assay, based on the previous study
[20]. These cutoff values were obtained by adding 3
times the standard deviation (SD) to the mean read-out
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of 37 HIV-negative sera (of the in-house panel) in the
one-step r-Δgp160- (mean = 598 cps; SD = 134 cps),
two-step r-Δgp160- (mean = 509 cps; SD = 138 cps), and
two-step r-HIV-1env- (mean = 577 cps; SD = 80 cps)
antigen based assays described above. The use of three
times SD to determine the cutoff value was based on a
preliminary characterization of the assay with seronega-
tive samples (n=37). Serum samples with ‘signal-to-cutoff ’
(S/Co) ratios of <1.0 were designated as negative, while
those with S/Co≥1.0 were designated as positive. Statis-
tical significance of differences in sensitivities between
assays was assessed using two-tailed Student’s t test. Dif-
ferences were considered to be of statistical significance
when the probability (p) was <0.05.
Results and discussion
Recombinant gp160 antigens
The two HIV-1 gp160 antigen variants, r-Δgp160 and
r-Trx-BAP-Δgp160, created for this study are shown
schematically in Figure 1. Both were designed to delete
the amino-terminal signal peptide and two internal
hydrophobic stretches of the native HIV-1 gp160 mol-
ecule without disruption of the reading frame. Add-
itional sequences were added to these through the use
of distinct expression vectors. Both were provided with
6x-His tags to facilitate purification. The key difference
between the two was that the r-Trx-BAP-Δgp160 vari-
ant also contained at its amino terminus a thioredoxin
(Trx)-biotin acceptor peptide (BAP) fusion partner. The
purpose of the Trx moiety was to promote solubility of
the recombinant antigen and thus facilitate its in vivo
biotinylation at the target site provided by BAP. The
two antigens were expressed by IPTG induction of
BL21(DE3) host cells harboring the cognate expression
constructs. In the case of r-Trx-BAP-Δgp160, bacterial
biotin ligase was co-expressed to mediate biotinylation
of its BAP moiety. An SDS-PAGE analysis of aliquots of
cells before and after induction of expression of the
r-Δgp160 and r-Trx-BAP-Δgp160 constructs is shown
in Figure 2. It was difficult to discern the presence of a
distinct induced polypeptide of the predicted molecular
Native HIV-1 gp160
aa 1 854
r-Trx-BAP- gp160
BAP
Trx
44 51
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Figure 1 Design of r-Δgp160 and r-Trx-BAP-Δgp160 antigens and TRF assay. The left part of the figure shows a schematic representation of
the native HIV-1 gp160 molecule. The black and grey boxes denote the signal sequence and the two internal hydrophobic regions in the
C-terminal half of native gp160, respectively. Depicted in the middle part of the figure are the two recombinant antigens created for this study,
r-Δgp160 and r-Trx-BAP-Δgp160. Both lack the signal sequence (black box) and the two internal hydrophobic regions (grey boxes) of native gp160.
An additional sequence consisting of thioredoxin (Trx) and biotin acceptor peptide (BAP) was fused to the N-terminus in r-Trx-BAP-Δgp160. Both
proteins were provided with 6x-His tags whose positions are indicated by the asterisks. The numbers indicate the starting and ending aa residues of
the native gp160 sequences retained, and fused in-frame, in the recombinant antigens. Shown to the right is design of the double antigen sandwich
assay: the r-Δgp160 and r-Trx-BAP-Δgp160 antigens were labeled with Eu3+-chelate and biotin isothiocyanate, respectively. These labeling reactions
(denoted by 1 and 2) produced r-Δgp160-Eu3+ (3) and r-Δgp160-Bio (4). The biotinylated capture antigen r-Δgp160-Bio was bound to SA (6) coating
the microtiter well surface (5). Serum anti-HIV-1 IgG (7) and IgM (8) that are captured in the wells are revealed using the tracer, r-Δgp160-Eu3+ (3),
and visualized by excitation at 340 nm followed by time-resolved measurement of fluorescence at 615 nm.
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Figure 2 SDS-PAGE analysis of r-Δgp160 and r-Trx-BAP-Δgp160
antigens. Aliquots of total lysates of E. coli harboring the r-Δgp160
and r-Trx-BAP-Δgp160 antigen constructs, before (lanes ‘U’) and after
(lanes ‘I’) IPTG induction, and aliquots of the affinity-purified antigens
(lanes ‘P’), were electrophoresed on denaturing gels and visualized
by Coomassie staining. Protein size markers were run in lane ‘M’;
their sizes (in kDa) are shown on the left. The arrows shown on the
right denote r-Trx-BAP-Δgp160 (upper) and r-Δgp160 (lower),
respectively. The asterisk denotes the position of biotin ligase
enzyme.
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weights in both cases, though an additional band of
~34 kDa, consistent with the size of biotin ligase, was
clearly seen in cells harboring the r-Trx-BAP-Δgp160
construct. Immunoblot analyses of these induced lysates
with a monoclonal antibody specific to the 6x-His tag
revealed that both r-Δgp160 and r-Trx-BAP-Δgp160 anti-
gens are indeed present in the induced lysates. However,
both recombinant antigens were found to be associated
with the insoluble fraction (data not shown). Apparently,
the Trx fusion is ineffective in promoting solubility of
r-Δgp160 antigen. This is consistent with the previous
observations that E. coli-expressed Trx fusion antigens
are not necessarily soluble [20,21]. Therefore, we
attempted to purify these antigens under denaturing con-
ditions. This resulted in near homogenous preparations
of the two antigens, as evidenced by the SDS-PAGE pro-
files of the pooled peak fractions in Figure 2 (lanes
marked ‘P’). The observed mobilities of purified r-Δgp160
and r-Trx-BAP-Δgp160 were consistent with their pre-
dicted sizes of ~88 and ~109 kDa, respectively. Our data
show that deletion of the hydrophobic regions is compat-
ible with the expression of r-Δgp160 variants in E. coli.
Starting from 1L induced E. coli cultures we obtained
~20 and ~15 mg, respectively, of purified r-Δgp160 and
r-Trx-BAP-Δgp160. However, as purifications were car-
ried out in the presence of urea, it had to be removed
from the purified antigens prior to their labeling for use
in the double antigen sandwich assays (below). We did
not determine if the purified proteins are correctly folded
and retained the integrity of their conformational epi-
topes. However, the recognition of linear epitopes by their
cognate antibodies may be sufficient to develop a sensi-
tive immunoassay. Further, the hydrophobic regions
deleted in r-Δgp160 are not exposed in the native struc-
ture of the full-length protein and therefore not expected
to contribute to immunoreactivity [25]. It is relevant to
point out that expression of full-length HIV-1 gp160 in
E. coli has not been possible thus far due to instability/
toxicity issues related to full-length, in-frame gp160 gene
[19]. In mammalian cells, gp160 undergoes proteolysis in
the Golgi complex to produce gp120 and gp41. It was
shown recently that when gp120 is expressed in the ab-
sence of gp41 in mammalian cells it forms aberrant disul-
fide linked dimers [26]. Further, it has been reported that
gp41 which can be expressed in E. coli, is associated with
inclusion bodies regardless of whether it has a GST fusion
partner [27,28]. Purification under denaturing conditions
was reported to yield ~5 mg [28] to ~12 mg [27] soluble
protein/L of bacterial cell culture.
Design of double antigen sandwich TRF assays
Having obtained the pair of gp160-based recombinant
antigens described above, we set up a TRF double anti-
gen sandwich assay [20]. In this instance, r-Trx-BAP-
Δgp160 was immobilized onto SA-coated plates and
0 30 60
0
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160
240
0 30 60
0
80
160
240
S/
Co
 ra
tio
s
Sample Number
A B
Figure 3 Analysis of an in-house sera panel using the one- and
two-step double antigen sandwich TRF assays. A panel of 59 in-
house assembled patient sera pre-screened for HIV-sero-status using
a commercial kit (Vidas HIV Duo Quick kit, bioMérieux SA, France),
were tested using the one-step (panel A) and two-step (panel B)
assays. The empty and filled circles represent sera that were
negative and positive, respectively, for anti-HIV-1 antibodies, as
determined by the two assays.
Table 1 Evaluation of r-Δgp160-based TRF assays using HIV-1 seroconversion panel (PRB 931)
Member
ID#
Days
since 1st
bleed
Abbott Gen. Sys. Organon
Teknika
HIVa
TRF assaysb
HIV1a HIV1/2a HIV1a HIV1/2a r-Δgp160
two-step
r-Δgp160
one-step
01 0 0.2 0.1 0.2 0.1 0.3 0.9 (−) 0.5 (−)
02 2 0.2 0.1 0.1 0.1 0.3 0.8 (−) 0.5 (−)
03 7 0.2 0.1 0.2 0.1 0.4 0.8 (−) 0.4 (−)
04 9 0.2 0.1 0.2 0.1 0.3 0.8 (−) 0.5 (−)
05 15 0.2 0.1 0.2 0.1 0.3 0.7 (−) 0.5 (−)
06 28 0.9 6 0.3 0.4 0.6 17.2 (+) 5.6 (+)
07 33 3.9 >18.7 0.8 1.1 2.3 15.9 (+) 4.3 (+)
08 35 5.7 >18.7 1.3 1.9 3.1 11.9 (+) 3.3 (+)
09 42 10.5 >18.7 2.9 4 4.6 13.8 (+) 2.9 (+)
aValues indicate S/Co ratios, provided by the panel supplier using the indicated commercial EIA kits. S/Co values ≥ 1.0 are considered as positive.
bValues indicate S/Co ratios obtained using r-Δgp160-based TRF assays. The results are indicated in parentheses. Samples with S/Co values < 1.0 are designated as
negative (−) and those with values ≥ 1.0 are designated as positive (+).
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used to capture anti-HIV antibodies, and r-Δgp160-Eu3+
was employed in TRF assay to detect the captured anti-
bodies. We have found in earlier work that immobilizing
the biotinylated capture antigen on SA-coated plate
enhances the sensitivity of the assay [29]. Surprisingly,
initial assays revealed that this assay was untenable as it
required very high amounts of r-Trx-BAP-Δgp160 anti-
gen to obtain acceptable signal to background ratios.
Further investigation showed this to be a result of low
levels of in vivo biotinylation of this antigen (data not
shown). The reason for this is not clear, though pre-
sumably it may be a reflection of the large size of the
antigen, about twice as large as the in vivo biotinylated
HIV-1 and −2 gp160 deletion variants reported earlier
[20], and its intrinsic insolubility. It may also have been
due to inaccessibility of the BAP moiety placed between
the Trx and Δgp160 components of the chimeric protein.
However, we think this is unlikely as similar internal
positioning of BAP did not compromise biotinylation in
our earlier studies [20,21]. To compensate for the lack of
in vivo biotinylation, we resorted to in vitro biotinylation
of this antigen. The resultant in vitro biotinylated deriva-
tive, r-Δgp160-Bio, was used (in place of the initially
intended r-Trx-BAP-Δgp160) in the double antigen
sandwich TRF assay outlined above (Figure 1). Using
r-Δgp160-Bio antigen immobilized on SA-coated plates,
we tested sera for anti-HIV antibodies using either a one-
step or two-step assay protocol. In the former, serum and
r-Δgp160-Eu3+ antigen were added together into the
microtiter well containing SA-immobilized r-Δgp160-Bio,
whereas in the latter a wash step was introduced after
serum addition, and then followed by the addition of the
r-Δgp160-Eu3+ antigen. The performance of both these
assays utilizing the r-Δgp160 antigen pair above, against
a large panel of well-characterized sera (n=131) was ana-
lyzed as described below.
Table 2 Evaluation of r-Δgp160-based TRF assays using worldwide HIV performance panel (WWRB 302)
Member
ID#
Origin Gtpa Abbott Gen. Sys. OT
HIV1b
TRF assaysc
HIV1b HIV1/2b HIV1b HIV1/2b r-Δgp160
two-step
r-Δgp160
one-step
01 Spain O 1.1 1.8 0.8 5.6 1.3 1.3 (+) 0.6 (−)
02 Ghana A >11.5 >16.1 6.9 8.7 7.0 94.0 (+) 9.2 (+)
03 Ghana G >11.5 >16.1 7.1 8.8 7.2 164.8 (+) 41.6 (+)
04 Ghana G >11.5 >16.1 7.1 8.8 6.5 138.0 (+) 4.1 (+)
05 Ghana A >11.5 >16.1 7.1 8.7 7.0 253.6 (+) 82.2 (+)
06 Ghana G >11.5 >16.1 6.9 8.8 7.1 91.4 (+) 15.1 (+)
08 Ivory Coast G >11.5 >16.1 6.9 8.7 6.7 73.0 (+) 4.4 (+)
09 Ivory Coast A >11.5 >16.1 6.9 8.6 6.5 107.8 (+) 3.9 (+)
10 Ivory Coast Neg 0.4 0.2 0.1 0.4 0.4 0.7 (−) 0.4 (−)
11 Mozambique HIV-2 1.2 14.6 0.6 9.7 3.0 1.0 (+) 0.7 (−)
12 Mozambique C >11.5 >16.1 7.1 8.9 6.9 187.1 (+) 4.1 (+)
14 Uganda D >11.5 >16.1 4.5 8.5 6.2 53.3 (+) 13.8 (+)
15 Uganda D >11.5 >16.1 6.3 8.1 7.2 132.9 (+) 16.8 (+)
16 Uganda D >11.5 >16.1 7.0 8.8 6.9 154.5 (+) 7.3 (+)
17 Uganda D >11.5 >16.1 6.8 9.8 7.0 131.2 (+) 5.1 (+)
19 Zimbabwe C >11.5 >16.1 6.0 9.9 7.0 41.4 (+) 10.3 (+)
21 China B >11.5 >16.1 6.7 8.8 7.0 136.7 (+) 26.8 (+)
22 Thailand E >11.5 >16.1 7.3 9.8 7.0 100.8 (+) 7.0 (+)
24 Thailand E >11.5 >16.1 7.4 9.8 6.9 88.4 (+) 23.2 (+)
25 India HIV-2 0.4 15.4 3.8 10 2.1 4.9 (+) 1.5 (+)
26 USA D >11.5 >16.1 7.4 9.8 7.1 85.8 (+) 48.5 (+)
27 USA B/D >11.5 >16.1 7.0 9.8 7.2 135.7 (+) 12.7 (+)
28 Argentina F >11.5 >16.1 7.0 8.9 6.8 72.5 (+) 3.0 (+)
29 Argentina B >11.5 >16.1 6.9 8.5 6.6 92.9 (+) 2.2 (+)
30 Argentina Neg 0.3 0.2 0.2 0.2 0.4 0.9 (−) 0.4 (−)
aGenotype.
bValues indicate S/Co ratios, provided by the panel supplier using the indicated commercial EIA kits. S/Co values ≥ 1.0 are considered as positive. (Gen. Sys.,
Genetic Systems; OT, Organon Teknika).
cValues indicate S/Co ratios obtained using r-Δgp160-based TRF assays. The results are indicated in parentheses. Samples with S/Co values < 1.0 are designated as
negative (−) and those with values ≥ 1.0 are designated as positive (+).
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Performance evaluation of the r-Δgp160-based one- and
two-step double antigen sandwich TRF assays
First, we carried out the one- and two-step assays out-
lined above using a panel of 59 in-house human sera
that had been pre-screened with the commercially avail-
able Vidas HIV Duo Quick kit, shown in Figure 3. Based
on the results with this kit, 22 sera were positive and 37
negative for anti-HIV antibodies. Remarkably, these
results were mirrored exactly by both the one- and two-
step r-Δgp160-based TRF assays, with no discrepancy in
any of the samples whatsoever.
The results with the in-house sera panel warranted
additional evaluation. For this purpose, we tested several
commercially procured well-characterized sera panels
described earlier [20]. To begin with, the sensitivities of
the one- and two-step assays were evaluated using a
HIV-1 seroconversion panel consisting of 9 samples
(PRB 931). Only one out of five currently used commer-
cial kits is capable of detecting seroconversion on day
28, represented by panel member #06. The data sum-
marized in Table 1 show that both the in-house assays
picked up panel member #06 unambiguoulsy, demon-
strating that they are as good as the best performing
Abbott HIV-1/2 kit in this regard. The capacity to detect
early seroconversion may be attributable to the inherent
design of the double antigen sandwich assay format
which narrows down the seroconversion window due to
its ability to pick up both IgM and IgG antibodies
[20,30]. The two-step assay displayed relatively higher
S/Co ratios. Next, we analyzed a worldwide panel
(WWRB 302) consisting of 21 HIV-1-positive, 2 HIV-2-
positive and 2 HIV-negative sera, from multiple
Table 3 Evaluation of r-Δgp160-based TRF assays using viral co-infection performance panel (PCA 201)
Member
ID#
Ortho
EIA
HCVa
Abbott
EIA
HBsAga
OT
Anti-HBca
HTLV HIV-1 TRF assaysb
Abbott
EIAa
GS
Blotsa
Abbott
EIAa
Dupont
blotsa
r-Δgp160
two-step
r-Δgp160
one-step
1 + + + + P 0.2 N/A 0.9 (−) 0.6 (−)
2 - + + - N/A 13.5 P 96.5 (+) 6.5 (+)
3 + + + + P 0.1 N/A 0.5 (−) 0.7 (−)
4 - + + + P 0.1 N/A ND ND
5 + - + + P 13.5 P 122.6 (+) 8.5 (+)
6 - - - - N/A 0.1 N/A ND ND
7 + - - + P 13.5 P 146.1 (+) 9.0 (+)
8 + + + - N/A 13.5 P 208.4 (+) 5.2 (+)
9 + + - + P 13.5 P 107.7 (+) 8.5 (+)
10 - + + - N/A 13.5 P 84.9 (+) 13.3 (+)
11 + + + + P 0.1 N/A 0.7 (−) 0.6 (−)
12 + + + - N/A 13.5 P 142.2 (+) 1.1 (+)
13 - + + - N/A 13.5 P 47.8 (+) 11.2 (+)
14 - + + + P 0.32 N/A 0.8 (−) 0.7 (−)
15 + + + + IND 0.2 N/A 0.8 (−) 0.7 (−)
16 + - + + P 13.5 P 182.5 (+) 4.5 (+)
17 + + + - N/A 13.5 P 215.4 (+) 9.1 (+)
18 + + - + P 13.5 P 48.3 (+) 3.6 (+)
19 - + + - N/A 13.5 P 88.2 (+) 9.7 (+)
20 - + + - N/A 1.1 P 3.3 (+) 2.5 (+)
21 - + + - N/A 13.5 P 128.6 (+) 3.0 (+)
22 + + + - N/A 13.5 P 140.6 (+) 16.9 (+)
23 + + + + P 0.2 N/A 0.8 (−) 0.8 (−)
24 - - - - N/A 0.1 N/A 0.8 (−) 0.8 (−)
25 - + + - N/A 13.5 P 127.1 (+) 6.0 (+)
aAssays performed by Boston Biomedica Inc (now SeraCare Life Sciences) using commercial kits. Values for Abbott anti-HIV EIA represent S/Co ratios, provided by
the panel supplier. Results of other EIA tests, provided by panel supplier are indicated as either positive (‘+’, S/Co ≥ 1.0) or negative (‘-’, S/Co < 1.0) for simplicity.
HTLV and HIV-1 EIA positive samples were also tested in blot formats using kits from GS (Genetic Systems) and Dupont, respectively. ‘P’and ‘IND’ indicate the
positive and indeterminate results, respectively, depending upon the presence or absence of antigen bands in the blot assays. ‘N/A’ indicates not applicable.
(‘OT’, Organon Teknika; ‘GS’, Genetic Systems).
bValues indicate S/Co ratios obtained using r-Δgp160-based TRF assays. The results are indicated in parentheses. Samples with S/Co values < 1.0 are designated as
negative (−) and those with values ≥ 1.0 are designated as positive (+). ‘ND’ indicates ‘not determined’ due to lack of sample.
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locations in Asia, Africa, Europe, and North and South
America. The data are summarized in Table 2. But for
panel members #1 and #11, which were missed by the
one-step assay, all other HIV-positive samples were
picked out by both in-house assays. These two sera, one
corresponding to HIV-1 group O (panel member #01)
and the other to HIV-2 (panel member #11), were
scored as weakly positive by the two-step assay. On the
other hand, the HIV-2-positive panel member #25 was
detectable with both the assays. Given that our antigen
was not designed to pick up HIV-2, these results imply
cross-reactivity of r-Δgp160 with anti-HIV-2 antibodies.
Importantly, the two sera in this panel (members #10
and #30), which were HIV-negative in five different
commercial assays were scored as seronegative by both
our in-house assays. We then evaluated the specificity of
the in-house one- and two-step assays, using a viral co-
infection panel (PCA 201), consisting of 9 (of which 7
were available to us) HIV-negative and 16 HIV-positive
sera samples. Many of the panel members were also
seropositive for hepatitis B virus (HBV), hepatitis C
virus (HCV) and/or Human T cell Leukemia virus
(HTLV). Both assays recognized all HIV-1 seropositive
samples correctly, irrespective of the presence of
antibodies to other viruses, as shown in Table 3. It is
noteworthy that of the 7 HIV-negative sera tested, 6 had
evidence of other infections such as HCV, HBV or
HTLV. Yet, none of these were picked up by either in-
house assay, demonstrating the high degree of specificity
of these assays.
The data thus far reveal that both the one- and two-
step r-Δgp160-based double antigen sandwich TRF
assays performed reliably when tested on three different
commercially procured sera panels. Recently, we had
evaluated these same sera panels in a two-step TRF
assay based on a mixture of recombinant HIV-1 and
HIV-2 antigens [20]. As in the present study, the earlier
reported assay was also in a double antigen sandwich
format. At this point, we were interested to compare the
sensitivity of the earlier two-step assay with the current
one- and two-step assays. To this end, we analyzed an
anti-HIV-1 low titer performance panel of 15 members
(PRB 108), using all three assays. The earlier assay was
done as before in a two-step format, but using a single
antigen, r-HIV-1env (biotinylated antigen to capture and
Eu3+-chelate labeled antigen to reveal), instead of the
two antigen mixture. The results of this comparative
analysis are summarized in Table 4. Panel member #2
Table 4 Evaluation of different TRF assays using anti-HIV-1 low titer performance panel (PRB 108)
Member
ID #
Abbott
HIV 1/2a
Gen. Sys.
HIV 1/2a
Org. Tek.
HIV 1a
Bio-Rad HIV-1
Western
Blot Resultb
Roche PCR
HIV-1 RNA
test
copies/mlc
TRF assaysd
r-Δgp160
two-step
r-Δgp160
one-step
r-HIV-1env
two-step
1 5.5 >8.9 1.4 + 3x104 1.9 (+) 1.8 (+) 2.0 (+)
2 0.2 0.3 0.3 - BLD 0.8 (−) 0.6 (−) 0.7 (−)
3e NA NA 1.8 IND 5x101* 3.4 (+) 3.0 (+) 0.8 (−)
4e 11.9 >8.9 6.3 + 9x104 7.0 (+) 5.2 (+) 3.4 (+)
5 3.4 >8.9 3.2 + 5x101* 2.2 (+) 1.2 (+) 3.6 (+)
6 NA NA 1.2 IND 6x103 1.8 (+) 1.1 (+) 5.9 (+)
7f 5.3 >8.9 1.3 + 3x103 2.7 (+) 1.6 (+) 3.9 (+)
8f 8.0 >8.9 2.8 + 7x103 3.8 (+) 2.8 (+) 4.8 (+)
9 8.5 >8.9 0.7 + 2x103 1.9 (+) 1.1 (+) 7.2 (+)
10 8.6 >8.9 0.6 IND 3x105 1.7 (+) 1.2 (+) 13.2 (+)
11 NA NA 3.8 + 8x103 3.2 (+) 2.0 (+) 5.4 (+)
12 1.7 2.0 0.3 - 5x105 1.1 (+) 0.6 (−) 0.9 (−)
13 NA NA 0.9 IND 2x105 4.9 (+) 2.7 (+) 18.2 (+)
14g NA NA 0.4 - 3x105 1.4 (+) 1.0 (+) 1.1 (+)
15g 14.2 >8.9 1.8 IND >7x105 5.9 (+) 3.0 (+) 8.0 (+)
aValues indicate S/Co ratios, provided by the panel supplier using the indicated commercial EIA kits. S/Co values ≥ 1.0 are considered as positive. (Gen. Sys.,
Genetic Systems; Org.Tek., Organon Teknika). ‘NA’ indicates data ‘not available’ from the panel supplier.
bResult provided by the panel supplier using the indicated commercial test. ‘+’ and ‘–’ indicate the presence and absence, respectively, of antigen bands in the
Western blot assay. ‘IND’ indicates indeterminate result.
CResult provided by the panel supplier using the indicated commercial test. ‘BLD’ indicates that the RNA level is below the limit of detection. *Ultrasensitive
method was used (50–75,000 copies/ml).
dValues indicate S/Co ratios obtained in this study, using the in-house TRF assays. The results are indicated in parentheses. Samples with S/Co values < 1.0 are
designated as negative (−) and those with values ≥ 1.0 are designated as positive (+).
ePRB 108–4 is a bleed from the same donor as PRB 108–3 collected 17 months later.
fPRB 108–8 is a bleed from the same donor as PRB 108–7 collected 6 days later.
gPRB 108–15 is a bleed from the same donor as PRB 108–14 collected 7 days later.
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was unequivocally seronegative by the three commercial
EIAs: Abbott HIV-1/2, Genetic Systems HIV-1/2 and
Organon Teknika HIV-1 tests. None of the three in-
house TRF assays showed reactivity with this sample.
Panel member #3, a borderline sample which could not
be picked up by the r-HIV-1env-based assay, was identi-
fied unequivocally by both the one- and two-step r-
Δgp160-based assays. It is noteworthy that this panel
member is positive for HIV-1 RNA. Another borderline
sample, represented by panel member #12, was un-
detectable by r-HIV-1env-based assay and one-step
r-Δgp160-based assay, but identified as weakly positive by
the two-step r-Δgp160-based assay. Four samples (panel
member #9, 10, 13 and 14) that were HIV-1 RNA posi-
tive, but scored as negative by the Organon Teknika
HIV-1 EIA kit, were identified as seropositive for HIV-1
by all three in-house TRF assays. Based on the results in
Table 4, the order of performance of the three assays was:
r-Δgp160-based two-step assay>r-Δgp160-based one-step
assay>r-HIV-1env-based two-step assay.
Collectively the data presented so far indicate that the
two-step r-Δgp160-based assay performs better as an
HIV-1 diagnostic test. To delineate this aspect more
clearly, we compared the S/Co values obtained for the
entire collection of sera analyzed in this study (n=131),
using the one- and two-step r-Δgp160-based assays. This
is presented in Figure 4. The mean S/Co value for the
HIV positive serum samples (n = 79) using the two-step
r-Δgp160-based assay was 83.1 (95% CI: 69–97.2). The
corresponding value for one-step r-Δgp160-based assay
was 9.7 (95% CI: 7.1-12.3). Between the two assays, the
mean S/Co value was significantly higher in the two-step
assay than in one-step assay (p<0.001). We interpret this
as a manifestation of the high-dose Hook effect [31],
wherein sera with high titers of anti-HIV antibody, in
the context of the one-step assay, sequester the tracer
antigen, r-Δgp160-Eu3+, thereby precluding effective
double antigen sandwich formation, leading to lowered
S/Co values. This anomaly is eliminated in the two-step
assay by introducing an intermediate washing step which
removes excess antibody after the initial capture step,
before addition of the tracer antigen. However, one-step
assay saves time consumed in an additional incubation
step.
Conclusions
This study has shown the feasibility of overcoming the
barrier to HIV-1 gp160 expression in E. coli. It has been
demonstrated that deletion of discrete hydrophobic
regions can result in the expression of near full-length
gp160 in E. coli hosts, in reasonably high yields. Double
antigen sandwich assays in conjunction with TRF-based
detection unequivocally established the diagnostic poten-
tial of the E. coli-expressed r-Δgp160 antigen. The r-
Δgp160 antigen-based one- and two-step assays, were
compared with several commercial HIV detection assays
using a collection of 131 sera, and found to perform as
well or better. Both the assays detected early seroconver-
sion on par with the best commercial kit and in general
manifested a high degree of sensitivity and specificity.
The robust performance of the one-step assay suggests its
potential in envisaging a rapid point-of-care assay. The
two-step assay manifested a significantly higher mean
S/Co value than the one-step assay, presumably by elim-
inating the Hook effect. The r-Δgp160 antigen provides
the basis for a highly sensitive and specific HIV-1 diag-
nostic assay that has the potential to cut down test cost
by lowering the cost of antigen production. In conjunc-
tion with luminescent lanthanide-doped inorganic nano-
particles e.g. up-converting phosphors to label the tracer
antigen which can be detected with an inexpensive reader,
r-Δgp160 antigen may pave the way for an affordable test
in resource-poor regions where HIV-1 is prevalent.
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Figure 4 Comparison of the one- and two-step double antigen
sandwich TRF assays. The S/Co values of all sera (n=131) analyzed
in this study, using the one-step (x axis) and two-step (y axis) assay
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